Terns Pharmaceuticals, Inc. (TERN) Dividend History

Terns Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for metabolic and liver diseases. Based in the United States, the company leverages precision medicine and advanced research techniques to create targeted treatments aimed at unmet medical needs in conditions such as non-alcoholic steatohepatitis (NASH) and related metabolic disorders.

1065 East Hillsdale Blvd., Suite 100, Foster City, CA, 94404
Phone: 650-525-5535 EXT.101
Website:

Dividend History

Terns Pharmaceuticals, Inc. currently does not pay dividends

Company News

  • This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments

    Terns Pharmaceuticals has a promising GLP-1 weight-loss drug that could compete with treatments from Novo Nordisk and Eli Lilly. However, the company is still in early stages and faces risks, including the need for ongoing stock offerings to fund its cash-burning operations.

    The Motley Fool
    Featured Companies: LLY
  • Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now.

    Terns Pharmaceuticals, a pre-revenue weight loss biotech company, is worth considering as its lead candidate TERN-601 has shown promising phase 1 results, suggesting it could be competitive with other weight loss drugs on the market.

    The Motley Fool
    Featured Companies: LLY VKTX
  • Should You Invest in This Under-the-Radar Weight Loss Stock?

    Terns Pharmaceuticals, a small-cap biotech company, is developing an oral GLP-1 drug for weight loss. While the initial phase 1 results are promising, the company faces competition from larger players like Novo Nordisk, which has more resources to push its candidates through the development stages faster.

    The Motley Fool
  • 1 New Weight Loss Drug Stock to Buy Now With $1,000 and Hold for 5 Years or More

    Terns Pharmaceuticals is developing a promising weight loss therapy, TERN-601, which has shown competitive weight loss results and good tolerability in early-stage trials. The company has sufficient cash runway, but there are still risks associated with the drug's development. Overall, Terns is a compelling biotech stock pick for investors willing to be patient.

    The Motley Fool
  • Terns Announces Pricing of Upsized $150.15 Million Public Offering

    Terns Pharmaceuticals, a clinical-stage biopharmaceutical company, announced the pricing of its upsized underwritten public offering of 11,919,048 shares of its common stock at $10.50 per share, as well as pre-funded warrants to purchase 2,380,952 shares. The company intends to use the net proceeds to fund research, clinical trials, and development of its key product candidates.

    GlobeNewswire Inc.
Dividend data last updated 06/07/2025 14:37:00 UTC